Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

NCT04625985 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

DRUG: Metformin Glycinate
DRUG: Placebo oral tablet

Sponsor

Laboratorios Silanes S.A. de C.V.